Category: Type A Diabetes

Towards a first precision medicine Immunotherapy for the treatment of Type 1 Diabetes using Tersan’s Artificial Intelligence

Tersan’s KEM® Artificial Intelligence technology identified immunological changes, which are early indicators of clinical effects, for selected groups of patients in a first-in-human Phase 1b study. The potential for a selection biomarker in patients receiving this therapy transforms design options for Imcyse’s future clinical trials in T1D and additional indications. On August 27th 2019, Imcyse, […]